PCM
KDNY

Piermont Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Piermont Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-6,160
Closed -$351K – 277
2017
Q2 		$351K Sell
6,160
-1,020
-14% -$51.2K 0.1% 243
2017
Q1 		$386K Buy
+7,180
New +$406K 0.09% 239

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Piermont Capital Management's KDNY Position: Q3 2017 in Review

Piermont Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2017, closing a stake of 6,160 shares — an estimated $351K sold.

Piermont Capital Management first reported a position in KDNY in Q1 2017 and held it in 2 quarters. The position peaked at $386K in Q1 2017. 90 funds tracked by Wall St. Rank hold KDNY as of Q3 2017.

  • Piermont Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Piermont Capital Management sold 6,160 Chinook Therapeutics, Inc. Common Stock shares in Q3 2017, an estimated $351K.
  • Piermont Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • Piermont Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $386K in Q1 2017.
  • 90 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2017.

Based on Piermont Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.